

The Oncoguard[®] Liver test detects early-stage hepatocellular carcinoma (HCC) with high sensitivity across patient subgroups

An analysis of the cohorts within the recent clinical validation publication to assess the performance of the Oncoguard[®] Liver test, stratified by patient and tumor factors

Cases: 292 treatment-naïve HCC cases^a
(159 early-stage^b)

Controls: 649 at-risk patients with chronic liver disease but no HCC

Assessments:

- Early-stage HCC sensitivity and specificity for the Oncoguard[®] Liver test, GALAD^c, and AFP using established cut-off values^d across predefined patient subgroups: sex, age, race/ethnicity, body mass index (BMI), and liver disease etiology and severity
- Oncoguard[®] Liver test, GALAD, and AFP HCC sensitivity by tumor size



^aAmerican Association for the Study of Liver Diseases diagnostic criteria

^bBarcelona Clinic Liver Cancer stages 0 + A

^cGender, Age, AFP-L3, AFP, and Des-carboxy-prothrombin score

^dCutoff values: GALAD, ≥ -0.63 ; AFP, 20 ng/mL

[> See tumor size sensitivity results](#)

The Oncoguard[®] Liver
test demonstrated high
sensitivity for HCC across
all tumor sizes



Sensitivity by index lesion tumor size


Tumor Size (n)	Oncoguard [®] Liver test	GALAD	AFP
1.0 to <2 cm (51)	61 (47–73)	53 (40–66)	31 (20–45)
2.0 to <3 cm (76)	80 (70–88)	75 (64–83)	32 (22–43)
3.0 to <4 cm (33)	85 (69–93)	82 (66–91)	58 (41–73)
4.0 to <5 cm (32)	94 (80–98)	88 (72–95)	72 (55–84)
≥ 5 cm (100)	98 (93–99)	91 (84–95)	72 (63–80)

Oncoguard[®] Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI).


> See subgroup sensitivity results

High sensitivity for early-stage HCC across important patient subgroups

The Oncoguard[®] Liver test demonstrated high sensitivity for early-stage HCC across sex, age, race/ethnicity, body mass index, liver disease etiology and severity subgroups.



> Click on subgroup to view in detail



Legend: Oncoguard[®] Liver test GALAD (-0.63 cutoff) AFP (20ng/mL cutoff)

Oncoguard[®] Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI). | *number of cases
ASH: alcoholic steatohepatitis | HBV: hepatitis B virus | HCV: hepatitis C virus | NAFLD: Non-Alcoholic Fatty Liver Disease



> Learn more about the Oncoguard[®] Liver test

> Click on subgroup to view in detail



Sex

> Close



Oncoguard[®] Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI). *number of cases
ASH: alcoholic steatohepatitis | HBV: hepatitis B virus | HCV: hepatitis C virus | NAFLD: Non-Alcoholic Fatty Liver Disease


> Learn more about the Oncoguard[®] Liver test

> Click on subgroup to view in detail



Age

> Close



Oncoguard[®] Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI). *number of cases
ASH: alcoholic steatohepatitis | HBV: hepatitis B virus | HCV: hepatitis C virus | NAFLD: Non-Alcoholic Fatty Liver Disease




> Learn more about the Oncoguard[®] Liver test

> Click on subgroup to view in detail



Race/ethnicity

> Close



Oncoguard[®] Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI). *number of cases
ASH: alcoholic steatohepatitis | HBV: hepatitis B virus | HCV: hepatitis C virus | NAFLD: Non-Alcoholic Fatty Liver Disease


> Learn more about the Oncoguard[®] Liver test

> Click on subgroup to view in detail



BMI

> Close



Oncoguard[®] Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI). *number of cases
ASH: alcoholic steatohepatitis | HBV: hepatitis B virus | HCV: hepatitis C virus | NAFLD: Non-Alcoholic Fatty Liver Disease





> Learn more about the Oncoguard[®] Liver test

> Click on subgroup to view in detail



Liver disease etiology

> Close



Oncoguard® Liver test GALAD (-0.63 cutoff) AFP (20ng/mL cutoff)



Oncoguard® Liver test GALAD (-0.63 cutoff) AFP (20ng/mL cutoff)

Oncoguard® Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI). *number of cases
ASH: alcoholic steatohepatitis HBV: hepatitis B virus HCV: hepatitis C virus NAFLD: Non-Alcoholic Fatty Liver Disease



> Learn more about the Oncoguard® Liver test

> Click on subgroup to view in detail



Liver disease severity

> Close



LIVER DISEASE ETIOLOGY



LIVER DISEASE SEVERITY



Oncoguard[®] Liver test, GALAD, and AFP early-stage HCC sensitivity (%) with 95% confidence intervals (CI). *number of cases
ASH: alcoholic steatohepatitis | HBV: hepatitis B virus | HCV: hepatitis C virus | NAFLD: Non-Alcoholic Fatty Liver Disease

> Learn more about the Oncoguard[®] Liver test

oncoguard[®] liver

by EXACT SCIENCES



The Oncoguard[®] Liver test demonstrated consistently **high sensitivity for early-stage HCC detection across all tumor sizes and patient subgroups**, and may benefit a wide range of at-risk patients undergoing HCC surveillance.

[Read our related blog post](#), “From inception to practice—new insights from the development of a high-performance liquid biopsy test for the detection of early-stage HCC.”

[Download our white paper](#), “Early-Stage Detection of Hepatocellular Carcinoma: The Oncoguard[®] Liver Solution.”

[> Visit OncoguardLiver.com/providers](https://oncoguardliver.com/providers)

Reference: Chalasani NP, Porter K, Book AJ, Xiong KM, Ramasubramanian TS, Kiehl-Grevstad E, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. The multi-target hepatocellular carcinoma blood test provides high sensitivity for detecting early-stage hepatocellular carcinoma across important patient subgroups. Poster presented at: Digestive Disease Week 2022; May 21-24, 2022; San Diego, CA.

Image content features models and is intended for illustrative purposes only.

oncoguardliver.com

exactsciences.com

EXACT SCIENCES CORPORATION 5505 Endeavor Lane | Madison, WI 53719. Oncoguard is a registered trademark of Exact Sciences Corporation in the US. All third-party marks—® and ™—are the property of their respective owners. ©2022 Exact Sciences Corporation. All rights reserved. OL.00054.HCP 6/2022